Work

Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.3640

Authors: Filip Janku, Elena Elez, Gopa Iyer, Noboru Yamamoto, Daniel Shao-Weng Tan, Anastasios Stathis, Uz M. Stammberger, Helen Evans, Abdelkader Seroutou, Anna Mais, Martin H. Schuler

Institutions: The University of Texas MD Anderson Cancer Center, Vall d'Hebron Hospital Universitari, Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital, National Cancer Centre Singapore, Istituto Oncologico della Svizzera Italiana, Novartis Institutes for BioMedical Research, Essen University Hospital

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Novartis

OpenAlex ID: W3029624192

Cites:

Cited by: 26

Related to: 10